Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2017

01-08-2017 | Review Article

Therapy assessment in multiple myeloma with PET

Authors: Cristina Nanni, Elena Zamagni

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2017

Login to get access

Abstract

Multiple myeloma is a plasma cell dyscrasia producing bone lytic lesions. In recent years, a wide spectrum of therapeutic approaches are available to treat the disease: an accurate therapy assessment has, therefore, become of utmost importance. In this field, imaging is becoming a cornerstone, especially in association with clinical parameters. Among imaging procedures, FDG PET/CT is recognized to provide reliable information, achieved in a very safe and fast procedure.  The literature has produced very concordant results from different groups assessing the value of FDG PET/CT as a prognostic factor in general and in therapy assessment, but some issues remain regarding a standardization of image interpretation especially in borderline cases. So far, no data regarding nor other imaging compounds and the use of hybrid tomographs PET/MR are available to define therapy assessment in PET.
Literature
1.
go back to reference Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992;6:347–58.PubMed Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992;6:347–58.PubMed
2.
go back to reference Rajkumar SV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed Rajkumar SV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefPubMed
3.
go back to reference Durie BGM. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–43.CrossRefPubMed Durie BGM. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–43.CrossRefPubMed
4.
go back to reference Mahnken AH, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol. 2002;178:1429–36.CrossRefPubMed Mahnken AH, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol. 2002;178:1429–36.CrossRefPubMed
5.
go back to reference Avva R, Vanhemert RL, Barlogie B, Munshi N, Angtuaco EJ. CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol. 2001;22:781–5.PubMed Avva R, Vanhemert RL, Barlogie B, Munshi N, Angtuaco EJ. CT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol. 2001;22:781–5.PubMed
7.
go back to reference Pace L, et al. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med. 1998;25:714–20.CrossRefPubMed Pace L, et al. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med. 1998;25:714–20.CrossRefPubMed
8.
go back to reference Fonti R, et al. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med. 2001;28:214–20.CrossRefPubMed Fonti R, et al. Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med. 2001;28:214–20.CrossRefPubMed
9.
go back to reference Falcone C, Cipullo S, Sannino P, Restuccia A. Whole body magnetic resonance and CT/PET in patients affected by multiple myeloma during staging before treatment. Recenti Prog Med. 2012;103:444–9.PubMed Falcone C, Cipullo S, Sannino P, Restuccia A. Whole body magnetic resonance and CT/PET in patients affected by multiple myeloma during staging before treatment. Recenti Prog Med. 2012;103:444–9.PubMed
10.
go back to reference Bauerle T, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology. 2009;252:477–85.CrossRefPubMed Bauerle T, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology. 2009;252:477–85.CrossRefPubMed
11.
go back to reference Baur-Melnyk A, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008;190:1097–104.CrossRefPubMed Baur-Melnyk A, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008;190:1097–104.CrossRefPubMed
12.
go back to reference Lecouvet F, et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Br J Haematol. 1997;96:743–5.CrossRefPubMed Lecouvet F, et al. Long-term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma. Br J Haematol. 1997;96:743–5.CrossRefPubMed
13.
go back to reference Spinnato P, et al. Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81(12):4013–8 doi: 10.1016/j.ejrad.2012.06.028. Epub 2012 Aug 24. Spinnato P, et al. Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. Eur J Radiol. 2012;81(12):4013–8 doi: 10.​1016/​j.​ejrad.​2012.​06.​028.​ Epub 2012 Aug 24.
14.
go back to reference Rahmouni A, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol. 1993;160(5):1049–52. Rahmouni A, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol. 1993;160(5):1049–52.
15.
go back to reference Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.CrossRefPubMed Zamagni E, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.CrossRefPubMed
16.
go back to reference Zamagni E, et al. Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:e101–4.CrossRefPubMed Zamagni E, et al. Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:e101–4.CrossRefPubMed
17.
go back to reference Cavo M, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;8(4):e206–e217. Cavo M, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;8(4):e206–e217.
18.
go back to reference Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.CrossRefPubMed Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.CrossRefPubMed
19.
go back to reference Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMed
20.
go back to reference Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.CrossRefPubMed Zamagni E, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.CrossRefPubMed
21.
go back to reference Bartel TB, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.CrossRefPubMedPubMedCentral Bartel TB, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.CrossRefPubMedPubMedCentral
22.
go back to reference Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819–23.CrossRefPubMedPubMedCentral Usmani SZ, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819–23.CrossRefPubMedPubMedCentral
23.
go back to reference Nanni C, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–9.CrossRefPubMed Nanni C, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–9.CrossRefPubMed
24.
go back to reference Patriarca F, et al. The role of positron emission tomography with 18F-Fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015; doi:10.1016/j.bbmt.2015.03.001. Patriarca F, et al. The role of positron emission tomography with 18F-Fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015; doi:10.​1016/​j.​bbmt.​2015.​03.​001.
25.
go back to reference Dimitrakopoulou-Strauss A, et al. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34:576–84.CrossRefPubMed Dimitrakopoulou-Strauss A, et al. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34:576–84.CrossRefPubMed
26.
go back to reference Kumar S, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.CrossRefPubMed Kumar S, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.CrossRefPubMed
27.
go back to reference Derlin T, et al. Comparative diagnostic performance of (1)(8)F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol. 2013;23:570–8.CrossRefPubMed Derlin T, et al. Comparative diagnostic performance of (1)(8)F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol. 2013;23:570–8.CrossRefPubMed
28.
go back to reference Mesguich C, et al. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23.CrossRefPubMed Mesguich C, et al. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23.CrossRefPubMed
29.
go back to reference Nanni C, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21.CrossRefPubMed Nanni C, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21.CrossRefPubMed
30.
31.
go back to reference Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7:30.CrossRefPubMedPubMedCentral Lasnon C, Enilorac B, Popotte H, Aide N. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Res. 2017;7:30.CrossRefPubMedPubMedCentral
32.
go back to reference Nanni C, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5 Nanni C, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5
33.
go back to reference Lapa C, et al. 11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6:254–61.CrossRefPubMedPubMedCentral Lapa C, et al. 11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6:254–61.CrossRefPubMedPubMedCentral
34.
go back to reference Okasaki M, et al. Comparison of (11)C-4′-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Ann Nucl Med. 2015;29:224–32.CrossRefPubMed Okasaki M, et al. Comparison of (11)C-4′-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Ann Nucl Med. 2015;29:224–32.CrossRefPubMed
35.
go back to reference Zhu W, Dang Y, Ma Y, Li F, Huo L. 11C-Acetate PET/CT monitoring therapy of multiple myeloma. Clin Nucl Med. 2016;41:587–9.CrossRefPubMed Zhu W, Dang Y, Ma Y, Li F, Huo L. 11C-Acetate PET/CT monitoring therapy of multiple myeloma. Clin Nucl Med. 2016;41:587–9.CrossRefPubMed
Metadata
Title
Therapy assessment in multiple myeloma with PET
Authors
Cristina Nanni
Elena Zamagni
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3730-4

Other articles of this Special Issue 1/2017

European Journal of Nuclear Medicine and Molecular Imaging 1/2017 Go to the issue